UK markets close in 4 hours 45 minutes
  • FTSE 100

    7,360.83
    +63.68 (+0.87%)
     
  • FTSE 250

    21,772.77
    +320.27 (+1.49%)
     
  • AIM

    1,092.70
    +14.67 (+1.36%)
     
  • GBP/EUR

    1.1927
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.3453
    -0.0038 (-0.28%)
     
  • BTC-GBP

    27,015.28
    +1,732.79 (+6.85%)
     
  • CMC Crypto 200

    827.20
    +16.60 (+2.05%)
     
  • S&P 500

    4,410.13
    +12.19 (+0.28%)
     
  • DOW

    34,364.50
    +99.13 (+0.29%)
     
  • CRUDE OIL

    83.86
    +0.55 (+0.66%)
     
  • GOLD FUTURES

    1,838.60
    -3.10 (-0.17%)
     
  • NIKKEI 225

    27,131.34
    -457.03 (-1.66%)
     
  • HANG SENG

    24,243.61
    -412.85 (-1.67%)
     
  • DAX

    15,125.76
    +114.63 (+0.76%)
     
  • CAC 40

    6,855.15
    +67.36 (+0.99%)
     

Novartis CEO says no decision has been taken on Sandoz

  • Oops!
    Something went wrong.
    Please try again later.
Swiss drugmaker Novartis' logo is seen in Stein
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • NVS

ZURICH (Reuters) - Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.

"No decision has been taken on Sandoz, we continue to evaluate the options," Vas Narasimhan said at the J.P. Morgan Healthcare conference. He also said the Swiss drugmaker continued to look for value-creating bolt-on acquisitions.

(Reporting by Silke Koltrowitz; Editing by Michael Shields)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting